NASDAQ:GLPG
Galapagos NV Stock News
$28.63
-0.140 (-0.487%)
At Close: Apr 25, 2024
Galapagos increases share capital through subscription right exercises
09:01pm, Friday, 18'th Mar 2022 GlobeNewswire Inc.
Mechelen, Belgium; 18 March 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten
09:01pm, Friday, 18'th Mar 2022 GlobeNewswire Inc.
Mechelen, België; 18 maart 2022, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt een kapitaalverhoging aan als gevolg van de uitoefening van inschrijvingsr
Tracking David Einhorn's Greenlight Capital Portfolio - Q4 2021 Update
05:33am, Monday, 28'th Feb 2022 Seeking Alpha
David Einhorn's GLRE 13F stock portfolio value increased from $1.49B to $1.75B this quarter. The largest 3 positions are at ~48% of the portfolio.
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call Transcript
05:48pm, Friday, 25'th Feb 2022 Seeking AlphaGalapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call Transcript
12:48pm, Friday, 25'th Feb 2022
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call Transcript
Galapagos GAAP EPS of -€1.58, revenue of €484.85M
09:07pm, Thursday, 24'th Feb 2022 Seeking Alpha
Galapagos press release (GLPG): FY GAAP EPS of -€1.58.Revenue of €484.85M (+1.4% Y/Y).Cash and current financial investments of €4.7 billion on 31 December 2021Operational cash burn…
Galapagos 2021 results set stage for future growth
09:01pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
Key 2021 and post period events:
Resultaten Galapagos 2021 zetten de toon voor toekomstige groei
09:01pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
2021 belangrijkste en recente gebeurtenissen:
Galapagos: A History Of Disruptive Failures
06:36am, Tuesday, 22'nd Feb 2022
Galapagos has failed to prove the mettle of its R&D pipeline in most of the programs it ran.
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
01:00pm, Thursday, 17'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March
Amylyx Pharma
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
01:32pm, Sunday, 13'th Feb 2022 Benzinga
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate
Galapagos receives transparency notification from EcoR1 Capital
09:01pm, Thursday, 03'rd Feb 2022 GlobeNewswire Inc.
Mechelen, Belgium; 03 February 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from EcoR1 Capital, LLC.
Galapagos ontvangt transparantieverklaring van EcoR1 Capital
09:01pm, Thursday, 03'rd Feb 2022 GlobeNewswire Inc.
Mechelen, België; 03 februari 2022, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van EcoR1 Capital, LL
Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
09:01pm, Wednesday, 02'nd Feb 2022 GlobeNewswire Inc.
Mechelen, Belgium; 2 February 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will present data at the European Crohn’s and Colitis Organization (ECCO) annual congress taking place 16-19 Feb
Galapagos geeft meer inzicht in de behandeling van colitis ulcerosa op het jaarlijkse congres van de European Crohn's and Colitis Organization (ECCO)
09:01pm, Wednesday, 02'nd Feb 2022 GlobeNewswire Inc.
Mechelen, België; 2 februari 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) zal op het jaarlijkse congres van de European Crohn's and Colitis Organization (ECCO) dat plaatsvindt van 16-19 fe
